876322-59-7

Basic information

• Product Name: Benzamide, N-(3-bromo-4-methylphenyl)-3-(trifluoromethyl)-
• CAS NO: 876322-59-7
• Molecular Formula: C15H11BrF3NO
• Molecular Weight: 358.158
• Mol File: 876322-59-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzamide, N-(3-bromo-4-methylphenyl)-3-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N-(3-bromo-4-methylphenyl)-3-(trifluoromethyl)-(876322-59-7)
• EPA Substance Registry System: Benzamide, N-(3-bromo-4-methylphenyl)-3-(trifluoromethyl)-(876322-59-7)

Safety Data

• Hazardous Substances Data: 876322-59-7(Hazardous Substances Data)

Upstream product

• 7745-91-7 3-bromo-4-methylaniline 
• 454-92-2 3-(trifluoromethyl)benzoic acid 
• 2251-65-2 3-(Trifluoromethyl)benzoyl chloride 

Downstream Products

• 1238376-21-0 N-(3-(1H-indazol-6-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide 
• 1448315-38-5 N-{4-methyl-3-[6-(1H-pyrazol-4-yl)-1H-imidazo[1,2-b]pyrazol-1-yl]phenyl}-3-(trifluoromethyl)-benzamide 
• 1018467-70-3 N-(4-methyl-3-(5-methyl-2-(6-methylsulfanylpyrimidin-4-yl)-2H-pyrazol-3-ylamino)-phenyl)-3-trifluoromethylbenzamide 
• 1018473-13-6 N-(4-methyl-3-(1-methyl-4-(6-methylsulfanylpyrimidin-4-yl)-1H-pyrazol-3-ylamino)-phenyl)-3-trifluoromethylbenzamide 
• 1018473-09-0 N-(4-methyl-3-(2-methyl-4-(6-methylsulfanylpyrimidin-4-yl)-2H-pyrazol-3-ylamino)-phenyl)-3-trifluoromethylbenzamide 
• 876322-58-6 N-[4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-3-trifluoromethyl-benzamide 

Relevant articles and documents

Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma

Although lung adenocarcinoma patients have benefited from the development of targeted therapy, patients with lung squamous cell carcinoma (SqCC) have no effective treatment due to the complexity and heterogeneity of the disease. Therefore, basing on the genetic analysis of mutations in lung squamous cell carcinoma to design multi-target inhibitors represents a potential strategy for the medical treatment. In this study, through screening an in-house focused library, we identified an interesting indazole scaffold. And following with binding analysis, we elaborated the structure-activity relationship of this hit compound by optimizing four parts guided by the DDR2 enzymatic assay, which resulted in a potent lead compound 10a. We conducted further optimization of dual enzymatic inhibitions towards FGFR1 and DDR2, two important kinases in lung squamous cell carcinoma. Finally, from the cellular antiproliferative activity tests and in vivo pharmacokinetic test, 3-substituted indazole derivative 11k was found to be a promising candidate and subjected to in vivo pharmacology study with the mouse xenograft models, demonstrating profound anti-tumor efficacy. Additional in vitro druglike assessment reinforced that compound 11k could be valuable for SqCC drug development.

2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS

Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases. Formula (I):

CHEMICAL COMPOUNDS

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I): which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.